Trial
NCT04543188
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Malignant Melanoma
Intervention
PF-07284890
Why stopped
Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-23